Viking Therapeutics is making headway in the weight loss drug market; but even though the payoff is years away, there's still plenty of upside for investors
It might not be too late to get in on the party.
Viking Therapeutics is making notable advancements in obesity treatment with VK2735 and exploring strategic partnerships for its NASH program, positioning itself at the forefront of metabolic and endocrine...
Novo Nordisk dominates diabetes treatment and obesity care, but one clinical-stage pharma company could be the next breakout star.
The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.
Viking Therapeutics VKTX reported third-quarter 2024 loss per share of 22 cents, narrower than the Zacks Consensus Estimate of a loss of 24 cents. The company had incurred a loss of 23 cents per share...
/CNW/ -- USA News Group News Commentary – With more than 100 million Americans struggling with obesity, and obesity rates increasing on every continent, it's...
Regardless of who wins the presidency, investors are better off focusing on top growth stocks.
Viking recently announced the results of an early-stage clinical trial for VK0214.
We could be witnessing the birth of a major player in the biotech industry.